Example collocations logo

Antiretroviral in sentence

66 examples of Antiretroviral in a sentence

But even when health-care use would be expected to be equal, such as care for HIV/AIDS in Africa, gender-based expectations impede HIV-positive men from obtaining antiretroviral drugs proportionate to their needs.
This is as silly as contending that antiretroviral drugs won’t work in the region, and that treating HIV is all a giant plot on the part of big pharmaceutical companies.
Likewise, as of 2000, there were still no official donor-supported programs to enable poor Africans to receive antiretroviral treatment for AIDS.
Thanks in large part to the agenda-setting power of the MDGs, donor programs to fight AIDS began to be implemented, and more than six million Africans now receive antiretroviral treatment supported by official donor programs.
And, although the 2010 target of universal access to antiretroviral therapy for HIV/AIDS was not reached, 6.5 million people in developing regions had access by 2011, following an increase of more than 1.4 million in 2010 alone – the largest annual increase ever.
Partners in Health, the NGO led by Kim and his colleague, Harvard University’s Paul Farmer, had used antiretroviral medicines (ARVs) to treat around 1,000 impoverished HIV-infected rural residents in Haiti, and had restored them to health and hope.
A decade ago, fewer than 10,000 people were taking the new generation of antiretroviral drugs that suppress the disease and offer the promise of a normal life.
I was given an antiretroviral treatment called Post-Exposure (PEP) for a month and had to take time off work because of the drug’s side effects.
Three of five HIV-positive people still are not receiving antiretroviral therapy.
The first group comprises “post-treatment controllers,” in whom early treatment allowed for long-term control of the infection even after antiretroviral therapy was stopped.
The Tragic Cost of Being UnscientificPRINCETON – Throughout his tenure as South Africa’s president, Thabo Mbeki rejected the scientific consensus that AIDS is caused by a virus, HIV, and that antiretroviral drugs can save the lives of people who test positive for it.
New antiretroviral medicines had been developed and were being used in rich countries, but were too expensive for the poorest.
Back in 2000, before the Global Fund was established, infected people in developing countries died of AIDS without any chance to receive life-saving antiretroviral medicines.
By 2010, more than six million people in developing countries were receiving antiretroviral treatment.
According to UNAIDS, just 54% of HIV-positive adults, and only 43% of HIV-positive children, are currently receiving the antiretroviral therapies that save lives and prevent new infections.
Today, more than eight million people – nearly half of all patients receiving treatment for HIV in developing countries – depend on the antiretroviral treatments that we produce.
Since 2005, the number of people on antiretroviral therapies worldwide has grown by a factor of ten, to 21 million.
Antiretroviral therapies for children are a good example of these challenges.
In West and Central Africa, only 2.1 million of the 6.1 million people living with HIV were receiving antiretroviral therapy.
With no antiretroviral therapy, the prescription for HIV/AIDS was food and rest – meaning that infection essentially amounted to a death sentence.
Although contradictory views about how to treat HIV persisted, at least antiretroviral therapy has been available in some public facilities over the past decade.
Three approaches have helped to contain the spread: the provision of antiretroviral therapy by the government and donor agencies; better treatment of tuberculosis patients, who tend to contract HIV/AIDS as well; and a greatly expanded program to prevent mother-to-child transmission.
With almost two million patients now on antiretroviral treatment, annual AIDS-related deaths have fallen by around 100,000 since 2005.
The government has aligned its early antiretroviral treatment programs for existing sufferers, initiated in 2008, with early monitoring programs for pregnant women.
The discovery of the human immunodeficiency virus (HIV) as the cause of AIDS was followed by elucidation of its pathogenesis, natural history, and epidemiology, the creation of a diagnostic blood test, and the development of antiretroviral drugs.
In 1996, the approval of the first drug of a class called protease inhibitors led to the adoption of a multi-drug, anti-HIV regimen known as highly active antiretroviral therapy, or HAART.
Moreover, antiretroviral drugs given to pregnant HIV-infected women and newborns have proven enormously successful in preventing mother-to-child transmission of HIV.
But fewer than 25% of the people in these countries who need antiretroviral drugs are receiving them.
As a result of Global Fund programs, an estimated 2.5 million people are on antiretroviral AIDS therapy.
Without the great leap forward in antiretroviral therapy in the mid-1990s, we would not have the tools we have today to control HIV.
Back